Anant Wadhwa
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,457 of the $5,734 with a category attached, or 77.7%. 33 manufacturers reported payments, led by Boston Scientific at 26.5% of the total. Reporting peaked in 2022 at $2,102 and has fallen 78.6% since, to $449 in 2025.
Across 142 payments — averaging $40.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Medtronic$1K
- Abbott$485
- AbbVie$383
- EMD Serono, Inc.$325
- SK Life Science, Inc.$207
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$351%
- Travel & lodging$1,22521%
- Food & beverage$4,45778%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 15 | $1,518 |
| Medtronic(2 entities) | 20 | $1,228 |
| Abbott | 13 | $485 |
| AbbVie(2 entities) | 12 | $383 |
| EMD Serono, Inc. | 9 | $325 |
| SK Life Science, Inc. | 5 | $207 |
| Acadia Pharmaceuticals Inc | 8 | $189 |
| Genentech USA, Inc. | 5 | $184 |
| Kyowa Kirin, Inc. | 2 | $138 |
| Bristol Myers Squibb | 7 | $133 |
| UCB, Inc. | 4 | $102 |
| Amneal Pharmaceuticals LLC | 5 | $100 |
| Neurocrine Biosciences, Inc. | 3 | $76 |
| Biogen | 3 | $61 |
| Novartis | 2 | $60 |
| Teva Pharmaceuticals USA, Inc. | 4 | $56 |
| Neurelis, Inc. | 3 | $52 |
| Sanofi | 2 | $50 |
| Merz Pharmaceuticals, LLC | 2 | $49 |
| Sunovion Pharmaceuticals Inc. | 3 | $44 |
| Acorda Therapeutics, Inc | 2 | $35 |
| Argenx US, Inc. | 1 | $32 |
| Upsher-smith Laboratories LLC | 2 | $29 |
| Lilly USA, LLC | 1 | $26 |
| AstraZeneca | 1 | $22 |
| Greenwich Biosciences, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $22 |
| Banner Life Sciences, LLC | 1 | $21 |
| Adamas Pharmaceuticals, Inc. | 1 | $20 |
| TG Therapeutics, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Catalyst Pharmaceuticals, Inc. | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,734 in reported general payments places this provider in the 75th percentile of 59 neurology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 41 | $266,505 |
| RytaryCarbidopa/Levodopa | 103 | $194,303 |
| NuplazidPimavanserin Tartrate | 31 | $155,633 |
| Kesimpta PenOfatumumab | 14 | $111,475 |
| IngrezzaValbenazine Tosylate | 12 | $105,254 |
| Austedo XrDeutetrabenazine | 13 | $98,252 |
| Tetrabenazine | 24 | $39,575 |
| NeuproRotigotine | 38 | $36,884 |
| Glatiramer Acetate | 13 | $36,804 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 745 | $30,623 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 394 | $30,063 |
| MyrbetriqMirabegron | 27 | $17,570 |
| Nurtec OdtRimegepant Sulfate | 14 | $12,339 |
| Carbidopa | 14 | $10,309 |
| Modafinil | 49 | $8,946 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $56 | $364,75754 claims |
| Amneal Pharmaceuticals LLCRytary | $100 | $194,303103 claims |
| Acadia Pharmaceuticals IncNuplazid | $189 | $155,63331 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $76 | $105,25412 claims |
| UCB, Inc.Neupro | $102 | $36,88438 claims |
| Upsher-smith Laboratories LLCTopiramate | $29 | $46652 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 59 neurology providers in Idaho.
Other neurology in Boise
- Sergei KashirnyBoise$20K
- Jackie WhitesellBoise$2K
- Brittany LovascioBoise$2K
- Benjamin StewartBoise$2K
- Matthew TechyBoise$2K
- Kelly BlockBoise$2K
- Thomas StrobelBoise$1K
- Lukas ClarkBoise$1K
- James WhitesideBoise$1K
- Daniel SimmonsBoise$729
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.